Three SRC inhibitors, KX2-391, bosutinib, and saracatinib, which had undergone clinical trials for other cancer types [34], were chosen for testing of their anti-tumor effects on a panel of eight NPC cell lines. This evidence concerns the gene SRC and neoplasm.